(Q35097381)

6 August 2017

1 reference

title

Improving the evaluation of new cancer treatments: challenges and opportunities (English)

1 reference

6 August 2017

Mace L Rothenberg

1

1 reference

6 August 2017

David P Carbone

series ordinal

2

1 reference

6 August 2017

David H Johnson

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

Nature Reviews Cancer

1 reference

6 August 2017

3

1 reference

6 August 2017

303-309

1 reference

6 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1047

6 August 2017

0 references

cites work

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

31 March 2020

1 reference

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

31 March 2020

1 reference

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

31 March 2020

1 reference

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

31 March 2020

1 reference

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

31 March 2020

1 reference

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

31 March 2020

1 reference

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

31 March 2020

1 reference

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

31 March 2020

1 reference

Matrix metalloproteinases: biologic activity and clinical implications

31 March 2020

1 reference

Clinical translation of angiogenesis inhibitors

31 March 2020

1 reference

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

31 March 2020

1 reference

A molecular signature of metastasis in primary solid tumors

31 March 2020

1 reference

Influence of unrecognized molecular heterogeneity on randomized clinical trials

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

31 March 2020

1 reference

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

31 March 2020

1 reference

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

31 March 2020

1 reference

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

31 March 2020

1 reference

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1047

1 reference

6 August 2017

1 reference